Mission/Purpose: The mission of the Tumor Tissue Core Laboratory is to facilitate translational cancer research by collecting and supplying high quality, well annotated human tissues (neoplastic and normal) to CCCWFU investigators. The Tumor Tissue Core carries out this mission by maintaining a repository of patient-derived tumors and matched normal tissues that are accompanied by pertinent clinical information, and by providing a Web-based database of available tumor and normal tissues for investigators to examine. Additionally, the Tumor Tissue Core assists investigators with custom collection of fresh human tissue samples for prospective translational research projects. The Tumor Tissue Core collaborates with the Cancer Biomedical Informatics Grid (caBIG?) initiative to link the core with other such repositories, nationally. Assets: The Tumor Tissue Core maintains a Web-based database for interaction of investigators with Core personnel and access to banked tissue inventories, as well as a functional instance linked to the caBIG? grid. The Tumor Tissue Core Laboratory is based in a fully functional research laboratory located on the 4th floor of the Hanes Building for processing tumor tissue samples. Presently, the Core maintains four -80?C freezers. Additionally, the Core has access to a Hacker motor-driven cryostat (maintained by the Cellular Imaging Core), an Agilent BioAnalyzer for RNA quality analysis (maintained by the MicroArray Core) and an Arcturus Pixcell ll/Olympus laser capture microscope for tissue microdissection (maintained by the Cellular Imaging Core). Usage: In the last year the Tumor Tissue Core collected 5354 tissue vials for research purposes. 1019 tissue vials were disbursed for 22 research projects. 88% of the disbursed tissue vials were utilized by CCCWFU members. The Tumor Tissue Core presently has over 22,000 tissue vials from >7000 patients, provided by 44 institutional surgeons. We have a comprehensive quality control protocol for monitoring sample quality. Future Directions: In the next funding cycle, the capabilities and utilization of the Tumor Tissue Core will be expanded by: (1) adding the caTIES and caARRAY modules that provide improved tissue annotation to the caTISSUE suite that is already grid enabled at our Cancer Center;(2) offering pilot fund RFA's to bolster the utilization of banked tissues;(3) increasing specimen utilization by the cancer genomics program that is part of the CCCWFU strategic plan;and (4) Adding a bar code scanner mechanism for more timely entry of collected sample information.

Public Health Relevance

This Shared Resource provides an adequate supply of high quality human tissue with appropriate annotation that is easily accessible by Cancer Center investigators. Successful grant applications and individual projects require a concerted effort by surgeons, pathologists, clinicians, basic scientists, and technicians to collect and maintain a biorepository that adheres to the best practices of human tissue collection. The Shared Resource at Wake Forest University School of Medicine has made it a priority to provide this service to its members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-39
Application #
8617229
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
39
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Xiao, Jiajie; Melvin, Ryan L; Salsbury Jr, Freddie R (2018) Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning. J Biomol Struct Dyn :1-18
Mao, Chengqiong; Zhao, Yan; Li, Fang et al. (2018) P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release 286:289-300
Diaz-Garelli, Jose-Franck; Wells, Brian J; Yelton, Caleb et al. (2018) Biopsy Records Do Not Reduce Diagnosis Variability in Cancer Patient EHRs: Are We More Uncertain After Knowing? AMIA Jt Summits Transl Sci Proc 2017:72-80
Wang, Mingxuan; Chen, Haiqin; Ailati, Aisikaer et al. (2018) Substrate specificity and membrane topologies of the iron-containing ?3 and ?6 desaturases from Mortierella alpina. Appl Microbiol Biotechnol 102:211-223
Westcott, Marlena M; Clemens, Elene A; Holbrook, Beth C et al. (2018) The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine 36:1174-1182
Ruiz, Jimmy; Miller, Antonius A; Tooze, Janet A et al. (2018) Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol :
Levine, Edward A; Votanopoulos, Konstantinos I; Shen, Perry et al. (2018) A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J Am Coll Surg 226:434-443
Addington, Elizabeth L; Sohl, Stephanie J; Tooze, Janet A et al. (2018) Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. Complement Ther Med 37:77-79
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681

Showing the most recent 10 out of 548 publications